Researchers at The University of Texas MD Anderson Cancer Center have characterized cancer cell-specific features in the tumor microenvironment (TME) of early-stage triple-negative breast cancer (TNBC) tissues, identifying specific macrophage subtypes associated with chemotherapy response.

An epigenetic mechanism by which tumors manage to hide from the body’s immune defences has just been described by an international scientific team led by the University of Liège and the Dana-Farber Cancer Institute. These findings open up avenues for new therapeutic strategies combining epigenetics and immunotherapy.

A new study by the Garvan Institute of Medical Research has uncovered a hidden mechanism explaining why breast cancer can return many years after successful treatment. Published in Nature Communications, the research revealed rogue cells that change their programming to allow them to divide at a remarkably slow pace, meaning they could form microscopic tumours that silently tick away in distant organs, evading detection for decades.